Polyclonal Gamma Delta T Cell Expansion Using Cytokine Cocktails
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding clinically relevant quantities of polyclonal γδ T cells for anti-tumor, anti-viral, and anti-bacterial reactivity are limited, as existing techniques fail to consistently achieve high frequencies of Vδ1 and Vδ1negVδ2neg subsets and do not produce cells that are suitable for clinical use due to low numbers and lack of comprehensive analysis of Vγ frequencies.
Innovation Solution
A method involving the use of artificial antigen presenting cells (aAPCs) and cytokines such as IL-2 and IL-21 to expand γδ T cells, which can be genetically edited to improve therapeutic potential, resulting in a cell composition with a polyclonal repertoire of Vδ and Vγ chains, including Vδ1, Vδ2, Vδ3, Vδ5, Vδ7, and Vδ8 with Vγ2, Vγ3, Vγ7, Vγ8, Vγ9, Vγ10, and Vγ11, and excluding NK cells and αβ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If aminobisphosphonates are used to propagate Vγ9Vδ2 T cells, then the Vγ9Vδ2 subset can be propagated for clinical use, but other γδ T cell lineages are not propagated and the therapy is not curative
Solution Approach 1:
The patent changes the chemical parameters of the culture medium by replacing aminobisphosphonates with a defined cytokine cocktail (IL-2, IL-7, IL-15, and IL-21) to enable propagation of diverse γδ T cell lineages beyond Vγ9Vδ2 while maintaining clinical relevance
Solution Approach 2:
The patent develops a universal expansion method using cytokine cocktails that can propagate multiple γδ T cell lineages (Vγ9Vδ2, Vδ1, Vδ3, and other subsets) simultaneously, creating a polyclonal product with broad therapeutic applicability rather than lineage-specific propagation
2Adaptability or versatility
If plate-bound antibodies and cytokine cocktails are used to propagate diverse γδ T cells, then a more diverse set of γδ T cells can be propagated, but the absolute numbers are not clinically relevant and the reagents are not available at GMP quality
Solution Approach 1:
The patent optimizes cytokine concentrations and culture conditions to achieve both high diversity of γδ T cell subsets and clinically relevant expansion numbers (≥10^9 cells), while using only GMP-available reagents for manufacturing scalability
Solution Approach 2:
The patent uses recombinant cytokines that can be produced at scale with consistent quality attributes, replacing limited-availability plate-bound antibodies with soluble cytokine formulations that are GMP-manufacturable and provide reproducible expansion results
3Manufacturing precision
If existing expansion methods are used, then some γδ T cells can be obtained, but they fail to consistently achieve high frequencies of Vδ1 and Vδ1negVδ2neg subsets and do not produce clinically relevant quantities
Solution Approach 1:
The patent adjusts cytokine ratios and culture parameters to simultaneously achieve high frequencies of desired subsets (Vδ1 and Vδ1negVδ2neg) and clinically relevant cell numbers, optimizing both quality and quantity metrics together rather than in isolation
Data Source
AI summary
Provided herein is a method of expanding clinically-relevant quantities of polyclonal γδ T cells that have anti-tumor, anti-viral, and anti-bacterial reactivity. Polyclonal γδ T cells can target a variety of tumors, including solid tumors as well as other conditions, such as viral and bacterial infections.